Back to search
FDAFDA · Food and drugs·Recall number D-0274-2021

Epoprostenol Sodium for Injection, 0.5 mg/vial (500,000 ng), 1X10ML vial, Rx only, Teva Pharmaceuticals USA, Inc., North Wales, PA 19454, NDC 0703-1985-01.

Published March 3, 2021 · Recall initiated: February 10, 2021

Summary

FDA records drug Class II recall D-0274-2021, published March 3, 2021 and initiated February 10, 2021. Recalling firm: Teva Pharmaceuticals USA; Status: Terminated; Reported quantity: 12,629 vials; Lot: Lot # 31327537B, exp. date 09/2021. Class II means possible temporary or medically reversible effects, or a remote probability of serious health consequences.

Status when published: Terminated — openFDA updates weekly, so this field may not reflect the current status. Always confirm with the official notice.

What's the hazard

Lack of Assurance of Sterility: manufacturing areas for the recalled products exceeded acceptance levels for microbial recovery leading to a lack of sterility assurance for these sterile injectable products.

What to do

Voluntary: Firm initiated · Letter

Get an email when a new FDA recall like this is published

Free. We only write when there's a new recall that matches. Unsubscribe in one click.

Recall details

Manufacturer
Teva Pharmaceuticals USA
Distributor
Product was distributed nationwide in the USA and Puerto Rico.
Lot
Lot # 31327537B, exp. date 09/2021
Risk classification
Class II
Area (FDA)
drug
Country
United States

Related recalls

Questions about this recall

Was Epoprostenol Sodium for Injection, 0.5 mg/vial (500,000 ng), 1X10ML vial, Rx only, Teva Pharmaceuticals USA, Inc., North Wales, PA 19454, NDC 0703-1985-01. recalled?

Yes. FDA published recall D-0274-2021 on March 3, 2021. Reported hazard: Lack of Assurance of Sterility: manufacturing areas for the recalled products exceeded acceptance levels for microbial recovery leading to a lack of sterility assurance for these sterile injectable products.

What should I do if I have this product?

Voluntary: Firm initiated · Letter